174 related articles for article (PubMed ID: 27817223)
21. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
[TBL] [Abstract][Full Text] [Related]
22. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
23. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.
Szajnik M; Czystowska-Kuźmicz M; Elishaev E; Whiteside TL
Expert Rev Mol Diagn; 2016 Aug; 16(8):811-26. PubMed ID: 27268121
[TBL] [Abstract][Full Text] [Related]
24. Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer.
Li J; Lin J; Luo Y; Kuang M; Liu Y
PLoS One; 2015; 10(6):e0130640. PubMed ID: 26107255
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Pelvic MRI and Serum Cancer Antigen-125: Selecting Women With Grade 1 Endometrial Cancer for Lymphadenectomy.
Sadowski EA; Robbins JB; Guite K; Patel-Lippmann K; Munoz del Rio A; Kushner DM; Al-Niaimi A
AJR Am J Roentgenol; 2015 Nov; 205(5):W556-64. PubMed ID: 26496578
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study.
Záveský L; Jandáková E; Turyna R; Langmeierová L; Weinberger V; Záveská Drábková L; Hůlková M; Hořínek A; Dušková D; Feyereisl J; Minář L; Kohoutová M
Pathol Oncol Res; 2015 Sep; 21(4):1027-35. PubMed ID: 25827090
[TBL] [Abstract][Full Text] [Related]
27. Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer.
Takac I; Gorisek B
Wien Klin Wochenschr; 2006; 118 Suppl 2():62-5. PubMed ID: 16817047
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Berezowska A; Radziszewski J; Bidzinski M; Kowalska M
PLoS One; 2017; 12(10):e0184576. PubMed ID: 28991928
[TBL] [Abstract][Full Text] [Related]
29. [Value of gynecological cytology and CA 125 level for the prediction of extrauterine malignancy in endometrial cancer].
Brassard L; Bessette P
J Obstet Gynaecol Can; 2012 Jul; 34(7):657-63. PubMed ID: 22742485
[TBL] [Abstract][Full Text] [Related]
30. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4.
Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
[TBL] [Abstract][Full Text] [Related]
31. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
32. Metabolomic Signature of Endometrial Cancer.
Troisi J; Sarno L; Landolfi A; Scala G; Martinelli P; Venturella R; Di Cello A; Zullo F; Guida M
J Proteome Res; 2018 Feb; 17(2):804-812. PubMed ID: 29235868
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.
Fan JT; Si XH; Liao Y; Shen P
Arch Gynecol Obstet; 2013 Jan; 287(1):111-5. PubMed ID: 22945838
[TBL] [Abstract][Full Text] [Related]
34. Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.
Presl J; Ovesna P; Novotny Z; Vlasak P; Bouda J; Kostun J; Topolcan O; Kucera R; Bednarikova M; Weinberger V
Anticancer Res; 2017 May; 37(5):2697-2702. PubMed ID: 28476847
[TBL] [Abstract][Full Text] [Related]
35. [The plasma levels and diagnostic utility of stem cell factor in patients with endometrial cancer and myoma uteri].
Ławicki S; Bedkowska GE; Gacuta-Szumarska E; Czygier M; Szmitkowski M
Pol Merkur Lekarski; 2009 Jun; 26(156):609-15. PubMed ID: 19711726
[TBL] [Abstract][Full Text] [Related]
36. Potential biomarkers in endometrial cancer: a narrative review.
Moar K; Pant A; Saini V; Maurya PK
Biomarkers; 2023 Jun; 28(4):358-371. PubMed ID: 36755526
[TBL] [Abstract][Full Text] [Related]
37. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.
Qu W; Li J; Duan P; Tang Z; Guo F; Chen H; Zhu X; Jiang SW
Expert Rev Mol Diagn; 2016 Dec; 16(12):1271-1282. PubMed ID: 27784171
[TBL] [Abstract][Full Text] [Related]
38. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
39. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.
Angioli R; Capriglione S; Scaletta G; Aloisi A; Miranda A; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2016 Apr; 37(4):4973-8. PubMed ID: 26531723
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study.
Kim HS; Park CY; Lee JM; Lee JK; Cho CH; Kim SM; Kim JW
Gynecol Oncol; 2010 Sep; 118(3):283-8. PubMed ID: 20541245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
